|
Papillary thyroid carcinoma
|
0.600 |
FusionGene
|
disease |
ORPHANET |
Our data reveal that both multiplex qPCR and FISH assays are equally applicable for detection of RET/PTC rearrangements.
|
25407564 |
2015 |
|
Papillary thyroid carcinoma
|
0.600 |
FusionGene
|
disease |
ORPHANET |
Molecular genetics of papillary thyroid carcinoma: great expectations.
|
17891228 |
2007 |
|
Papillary thyroid carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
On the contrary, genetic alterations in sporadic papillary thyroid carcinoma (PTC) are better characterized, the most common one involving the activation of the proto-oncogene RET through somatic rearrangements.
|
11463498 |
2001 |
|
Papillary thyroid carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Seventeen patients underwent a thyroid nodule FNAB (results: 12 benign, one follicular neoplasm, three suspicious for malignancy, and one papillary thyroid cancer [PTC]), from which six underwent thyroidectomy; PTC was confirmed by surgical pathology for all cases (8.5% of all nodules observed).
|
31461359 |
2020 |
|
Papillary thyroid carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The present study was designed to define the prevalence of RET expression in patients with papillary thyroid carcinoma, by immunohistochemistry and by RT-PCR; to search specifically for RET/PTC-1; -2; -3 rearrangements using RT-PCR, and to compare results obtained by immunohistochemistry with those obtained by RT-PCR.
|
12963982 |
2003 |
|
Papillary thyroid carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
This rearrangement could affect the ret-proto-oncogene, localized to 10q11.2 which is activated in some papillary thyroid carcinomas.
|
1745982 |
1991 |
|
Papillary thyroid carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Hence, our findings highly support the use of siRNA RET/PTC3-SQ NPs as a new promising treatment for patients affected by PTC expressing RET/PTC3.
|
24759995 |
2014 |
|
Papillary thyroid carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Adoptive activation of the RET/PTC-RAS-BRAF axis induced cell proliferation and Matrigel invasion of thyroid follicular cells.
|
15761501 |
2005 |
|
Papillary thyroid carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Since both PTC, a novel rearranged form of RET, and TRK display a tyrosine protein kinase activity, it is proposed that the activation of this class of oncogenes is specifically involved in the pathogenesis of papillary thyroid cancer.
|
2594368 |
1989 |
|
Papillary thyroid carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Our results suggest that the expression of rearranged RET hybrid oncogenes (1) is present in a similar percentage of HCCs when compared with the literature on nonoxyphilic PTCs, (2) defines PTC-like HCCs better than histomorphologic characterization, (3) excludes HCCs as a subgroup of FTCs, and (4) may play a role in the early tumorigenesis of oncocytic tumors.
|
14668719 |
2003 |
|
Papillary thyroid carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
These miRNAs were further validated by real-time RT-PCR in a cohort of 17 PTC with local tumor recurrence or distant metastases and 15 PTC with no extrathyroidal dissemination and correlated with BRAF, RAS, and RET/PTC mutations and MET expression.
|
21537871 |
2011 |
|
Papillary thyroid carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Comparison of the anaplastic thyroid cancer expression datasets with the papillary thyroid cancer and normal thyroid tissue transcriptomes suggested several known drug targets such as FGFRs, VEGFRs, KIT and RET to have lower expression levels in anaplastic specimens compared with both papillary thyroid cancers and normal tissues, confirming the observed lack of response to therapies targeting these pathways.
|
26680454 |
2015 |
|
Papillary thyroid carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The novel fusion was identified in a case of PTC that revealed a gene expression signature characteristic of RET/PTC on DNA microarray analysis, but was negative for the most common types of RET rearrangement.
|
17639057 |
2007 |
|
Papillary thyroid carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We have studied the expression of the RET encoded protein in 127 papillary thyroid carcinomas by immunohistochemistry using a polyclonal antibody against the tyrosine-kinase domain of the RET protein.
|
11720878 |
2001 |
|
Papillary thyroid carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemical analysis and polymerase chain reaction were used to determine activation of the RET/PTC-RAS-BRAF cascade in HT and PTC.
|
17900235 |
2007 |
|
Papillary thyroid carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
However, the potential associations between chemokine (C‑C motif) ligand 21 (CCL21)/C‑C chemokine receptor type 7 (CCR7) interaction and iodine concentrations in primary cultures of PTC with RET/PTC expression remain unclear.
|
27574129 |
2016 |
|
Papillary thyroid carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The RET proto-oncogene is often activated through somatic rearrangements in papillary thyroid carcinomas (PTCs).
|
10980597 |
2000 |
|
Papillary thyroid carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The oncogenic fusion protein RET/PTC3 (RP3) that is expressed in papillary thyroid carcinoma (PTC) and thyroid epithelia in Hashimoto's thyroiditis activates nuclear factor-kappa B (NF-κB) and induces pro-inflammatory gene expression; however, the mechanism of this activation is unknown.
|
20818435 |
2011 |
|
Papillary thyroid carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Almost half of the PTCs showed RET-TK expression; in only three was this explained by expression of a RET/PTC rearrangement.
|
11298625 |
2001 |
|
Papillary thyroid carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Moreover, nine of 60 PTCs (15%) presented RET/PTC expression.
|
15126572 |
2004 |
|
Papillary thyroid carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We detected RET transcription in approximately 85% of the PTCs including follicular variants and in isolated cells of the same tissues, but not in nonmalignant thyroid tissue.
|
11279350 |
2000 |
|
Papillary thyroid carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Three separate association analyses were carried out on the cohort evaluating the effects of, respectively, ret/PTC positivity, preferential RET tyrosine kinase domain (RET-TK) expression, and ret/PTC plus RET-TK positivity, on age, sex, tumor size, staging, number of neoplastic foci, and histological subtype.
|
12720532 |
2003 |
|
Papillary thyroid carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer.
|
15273715 |
2004 |
|
Papillary thyroid carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
RET oncogene expression of papillary thyroid carcinoma in Korea.
|
15170542 |
2004 |
|
Papillary thyroid carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
RET/PTC1 mRNA was detected in the peripheral blood of only one patient with papillary thyroid carcinoma.
|
9508203 |
1998 |